Biogen(NASDAQ:BIIB) rose ~5.0%on Friday to outperform the broader market for the week as it awaits FDA approval for aducanumab, the experimental therapy against Alzheimer’s disease co-developed by the...
网页链接Biogen(NASDAQ:BIIB) rose ~5.0%on Friday to outperform the broader market for the week as it awaits FDA approval for aducanumab, the experimental therapy against Alzheimer’s disease co-developed by the...
网页链接
精彩评论